These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27789100)

  • 21. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relationship between neurokinin B and endothelin-1 and hypertensive disorders complicating pregnancy].
    Li ZM; Zhao Y; Chen Q; Zou L; Wang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2008 Aug; 43(8):584-8. PubMed ID: 19087492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.
    Laganà AS; Vitale SG; Nigro A; Sofo V; Salmeri FM; Rossetti P; Rapisarda AM; La Vignera S; Condorelli RA; Rizzo G; Buscema M
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPAR activation as a regulator of lipid metabolism, nitric oxide production and lipid peroxidation in the placenta from type 2 diabetic patients.
    Capobianco E; Martínez N; Fornes D; Higa R; Di Marco I; Basualdo MN; Faingold MC; Jawerbaum A
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):7-15. PubMed ID: 23811234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function.
    Shomer E; Katzenell S; Zipori Y; Sammour RN; Isermann B; Brenner B; Aharon A
    Hypertension; 2013 Nov; 62(5):893-8. PubMed ID: 24082057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptors and angiogenesis.
    Biscetti F; Straface G; Pitocco D; Zaccardi F; Ghirlanda G; Flex A
    Nutr Metab Cardiovasc Dis; 2009 Dec; 19(11):751-9. PubMed ID: 19628379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Placental expression of VEGF family mRNA in adverse pregnancy outcomes.
    Andraweera PH; Dekker GA; Laurence JA; Roberts CT
    Placenta; 2012 Jun; 33(6):467-72. PubMed ID: 22386962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of placental fatty acid metabolism and regulation by peroxisome proliferator activated receptor on pregnancy and fetal outcomes.
    Xu Y; Wang Q; Cook TJ; Knipp GT
    J Pharm Sci; 2007 Oct; 96(10):2582-606. PubMed ID: 17549724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endothelial dysfunction in pregnancy metabolic disorders.
    Echeverria C; Eltit F; Santibanez JF; Gatica S; Cabello-Verrugio C; Simon F
    Biochim Biophys Acta Mol Basis Dis; 2020 Feb; 1866(2):165414. PubMed ID: 30794867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence implicating peroxisome proliferator-activated receptor-γ in the pathogenesis of preeclampsia.
    McCarthy FP; Drewlo S; English FA; Kingdom J; Johns EJ; Kenny LC; Walsh SK
    Hypertension; 2011 Nov; 58(5):882-7. PubMed ID: 21931072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PPARs: therapeutic targets for metabolic disease.
    Berger JP; Akiyama TE; Meinke PT
    Trends Pharmacol Sci; 2005 May; 26(5):244-51. PubMed ID: 15860371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maternal complications and perinatal outcomes associated with gestational hypertension and severe preeclampsia in Taiwanese women.
    Liu CM; Cheng PJ; Chang SD
    J Formos Med Assoc; 2008 Feb; 107(2):129-38. PubMed ID: 18285245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPAR ligands improve impaired metabolic pathways in fetal hearts of diabetic rats.
    Kurtz M; Capobianco E; Martinez N; Roberti SL; Arany E; Jawerbaum A
    J Mol Endocrinol; 2014 Oct; 53(2):237-46. PubMed ID: 25122159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Keeping the Balance Right: Regulator of G Protein Signaling 5 in Vascular Physiology and Pathology.
    Ganss R
    Prog Mol Biol Transl Sci; 2015; 133():93-121. PubMed ID: 26123304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia.
    Cerdeira AS; Karumanchi SA
    Scand J Clin Lab Invest Suppl; 2010; 242():73-8. PubMed ID: 20515282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.
    Cheang WS; Tian XY; Wong WT; Huang Y
    Br J Pharmacol; 2015 Dec; 172(23):5512-22. PubMed ID: 25438608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview on biological mechanisms of PPARs.
    Kota BP; Huang TH; Roufogalis BD
    Pharmacol Res; 2005 Feb; 51(2):85-94. PubMed ID: 15629253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Placental imbalance of Th1- and Th2-type cytokines in preeclampsia.
    Dong M; He J; Wang Z; Xie X; Wang H
    Acta Obstet Gynecol Scand; 2005 Aug; 84(8):788-93. PubMed ID: 16026406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Genetic variants of endothelial nitric synthase in gestational hypertension and preeclampsia].
    Perlik M; Seremak-Mrozikiewicz A; Barlik M; Kurzawińska G; Kraśnik W; Drews K
    Ginekol Pol; 2012 Sep; 83(9):652-9. PubMed ID: 23342892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.